Clo and Flu exposures as continuous variables are not associated with clinical outcome
| . | Clo . | Flu . | ||||
|---|---|---|---|---|---|---|
| P value univariable . | HR (95% CI) . | P value univariable . | HR (95% CI) . | P value multivariable . | HR (95% CI) . | |
| OS | .20 | 1.32 (0.88-1.97) | .50 | 1.06 (0.90-1.25) | - | - |
| EFS | .13 | 1.31 (0.94-1.83) | .37 | 1.07 (0.93-1.23) | - | - |
| GRFS | .20 | 1.26 (0.88-1.79) | .58 | 1.04 (0.90-1.2) | - | - |
| TRM | .98 | 1.01 (0.43-2.4) | .49 | 0.90 (0.65-1.24) | - | - |
| Relapse | .43 | 1.17 (0.79-1.74) | .27 | 1.09 (0.94-1.26) | - | - |
| Graft failure | .07 | 2.12 (1.00-4.49) | .21 | 1.27 (0.90-1.80) | - | - |
| aGvHD | .86 | 1.05 (0.62-1.78) | .93 | 0.99 (0.84-1.17) | - | - |
| cGvHD | .30 | 0.70 (0.36-1.37) | .18 | 0.72 (0.44-1.17) | - | - |
| CD4 IR | .41 | 1.14 (0.84-1.55) | .03∗ | 1.14 (1.02-1.276) | .18 | 1.08 (0.96-1.22) |
| . | Clo . | Flu . | ||||
|---|---|---|---|---|---|---|
| P value univariable . | HR (95% CI) . | P value univariable . | HR (95% CI) . | P value multivariable . | HR (95% CI) . | |
| OS | .20 | 1.32 (0.88-1.97) | .50 | 1.06 (0.90-1.25) | - | - |
| EFS | .13 | 1.31 (0.94-1.83) | .37 | 1.07 (0.93-1.23) | - | - |
| GRFS | .20 | 1.26 (0.88-1.79) | .58 | 1.04 (0.90-1.2) | - | - |
| TRM | .98 | 1.01 (0.43-2.4) | .49 | 0.90 (0.65-1.24) | - | - |
| Relapse | .43 | 1.17 (0.79-1.74) | .27 | 1.09 (0.94-1.26) | - | - |
| Graft failure | .07 | 2.12 (1.00-4.49) | .21 | 1.27 (0.90-1.80) | - | - |
| aGvHD | .86 | 1.05 (0.62-1.78) | .93 | 0.99 (0.84-1.17) | - | - |
| cGvHD | .30 | 0.70 (0.36-1.37) | .18 | 0.72 (0.44-1.17) | - | - |
| CD4 IR | .41 | 1.14 (0.84-1.55) | .03∗ | 1.14 (1.02-1.276) | .18 | 1.08 (0.96-1.22) |
Cox proportional hazards and Fine and Gray competing risk models were used for the evaluation of time-to-event data. Factors were entered into multivariable models if P value < .05. In multivariable analyses, ATG exposure was considered as covariable for CD4 IR. CD4 IR was defined as >50 CD4+ T cells per μL within 100 days after allo-HCT. P values < .05 were considered statistically significant.
OS, overall survival; EFS, event-free survival; GRFS, GVHD-free relapse-free survival, TRM, therapy-related mortality; aGvHD, acute GvHD; cGvHD, chronic GvHD; CD4 IR, CD4 immune reconstitution; CI, confidence interval; HR, hazard ratio; ∗, P < .05.